Takahashi-Yanaga, F. Activator or inhibitor? GSK-3 as a new drug target. Biochem Pharmacol
2013; 86: 191–9.
McCubrey, JA, Davis, NM, Abrams, SL, Montalto, G, Cervello, M, Basecke, J, et al. Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy. Adv Biol Regul
2014; 54: 176–96.
McCubrey, JA, Steelman, LS, Bertrand, FE, Davis, NM, Sokolosky, M, Abrams, SL, et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget
2014; 5: 2881–911.
Brown, KM, Tracy, DK. Lithium: the pharmacodynamic actions of the amazing ion. Ther Adv Psychopharmacol
2013; 3: 163–76.
Severus, E, Taylor, MJ, Sauer, C, Pfennig, A, Ritter, P, Bauer, M, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord
2014; 2: 1–17.
Cohen, Y, Chetrit, A, Cohen, Y, Sirota, P, Modan, B. Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med Oncol
1998; 15: 32–6.
Cheng, CL, Kao, YH, Lin, SJ, Lee, CH, Lai, ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf
2011; 20: 236–42.
World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD-9).
Young, LT. What exactly is a mood stabilizer?
J Psychiatry Neurosci
2004; 29: 87–8.
Bowden, CL. Anticonvulsants in bipolar disorders: current research and practice and future directions. Bipolar Disord
2009; 11: 20–33.
Deyo, RA, Cherkin, DC, Ciol, MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol
1992; 45: 613–9.
Gerhard, T, Devanand, DP, Huang, C, Crystal, S, Olfson, M. Lithium treatment and risk for dementia in adults with bipolar disorder: population-based cohort study. Br J Psychiatry
2015; 207: 46–51.
Pottegard, A, Friis, S, Andersen, M, Hallas, J. Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study. Br J Clin Pharmacol
2013; 75: 1356–64.
Brookhart, MA, Wyss, R, Layton, JB, Sturmer, T. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes
2013; 6: 604–11.
Austin, PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med
2013; 32: 2837–49.
Kaae, J, Carstensen, L, Wohlfahrt, J, Melbye, M, Boyd, HA. Epilepsy, antiepileptic medication use and risk of cancer. Int J Cancer
2014; 134: 932–8.
Singh, G, Bell, GS, Driever, PH, Sander, JW. Cancer risk in people with epilepsy using valproate-sodium. Acta Neurol Scand
2012; 125: 234–40.
Hallas, J, Friis, S, Bjerrum, L, Stovring, H, Narverud, SF, Heyerdahl, T, et al. Cancer risk in long-term users of valproate: a population-based case-control study. Cancer Epidemiol Biomarkers Prev
2009; 18: 1714–9.
Kang, H, Gillespie, TW, Goodman, M, Brodie, SA, Brandes, M, Ribeiro, M, et al. Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. Cancer
2014; 120: 1394–400.
Boursi, B, Lurie, I, Mamtani, R, Haynes, K, Yang, YX. Anti-depressant therapy and cancer risk: a nested case-control study. Eur Neuropsychopharmacol
2015; 25: 1147–57.
Lee, HK, Eom, CS, Kwon, YM, Ahn, JS, Kim, S, Park, SM. Meta-analysis: selective serotonin reuptake inhibitors and colon cancer. Eur J Gastroenterol Hepatol
2012; 24: 1153–7.
Walker, AJ, Card, T, Bates, TE, Muir, K. Tricyclic antidepressants and the incidence of certain cancers: a study using the GPRD. Br J Cancer
2011; 104: 193–7.
Fond, G, Macgregor, A, Attal, J, Larue, A, Brittner, M, Ducasse, D, et al. Antipsychotic drugs: pro-cancer or anti-cancer? A systematic review. Med Hypotheses
2012; 79: 38–42.
Lin, GM, Chen, YJ, Kuo, DJ, Jaiteh, LE, Wu, YC, Lo, TS, et al. Cancer incidence in patients with schizophrenia or bipolar disorder: a nationwide population-based study in Taiwan, 1997–2009. Schizophr Bull
2013; 39: 407–16.
Hung, Y-N, Yang, S-Y, Huang, M-C, Lung, F-W, Lin, S-K, Chen, K-Y, et al. Cancer incidence in people with affective disorder: nationwide cohort study in Taiwan, 1997–2010. Br J Psychiatry
2014; 205: 183–8.
Grunze, H, Vieta, E, Goodwin, GM, Bowden, C, Licht, RW, Moller, HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013; 14: 154–219.
Bai, YM, Chang, CJ, Tsai, SY, Chen, YC, Hsiao, MC, Li, CT, et al. Taiwan consensus of pharmacological treatment for bipolar disorder. J Chin Med Assoc
2013; 76: 547–56.
Rowe, MK, Wiest, C, Chuang, DM. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev
2007; 31: 920–31.